BioMarin Pharmaceutical Inc. filed a Form 8-K on August 31, 2026, disclosing that on August 30, 2026, it entered into a binding term sheet with Ascendis Pharma A/S to resolve all pending patent proceedings through a global settlement and royalty-bearing license agreement.

Key Highlights

  • Binding term sheet signed: BioMarin and Ascendis Pharma A/S executed a binding term sheet on August 30, 2026, covering a global settlement and license agreement.
  • Non-exclusive worldwide license granted: BioMarin will grant Ascendis a non-exclusive, worldwide, transferable, royalty-bearing license to certain BioMarin Patent Rights for Licensed Products including TransCon CNP, navepegritide, and Yuviwel.
  • Royalty rates set: Ascendis will pay BioMarin 20% of annual net sales in the United States and 18% in the European Union, Brazil, and South Korea, applied retroactively from first commercial sale in each territory until May 2030.
  • All litigation to be dismissed: The parties agreed to dismiss with prejudice all pending litigation between them relating to the BioMarin Patent Rights.
  • Agreement deadline of September 24, 2026: The parties agreed to negotiate a full agreement by September 24, 2026, after which the term sheet provisions remain binding if no agreement is reached.
  • No-challenge covenant included: Ascendis covenanted not to challenge BioMarin's Patent Rights, and BioMarin released claims for infringement prior to the August 30, 2026 effective date.

BioMarin and Ascendis Pharma Settle Patent Dispute Over CNP Product Rights

According to the filing, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) entered into a binding term sheet with Ascendis Pharma A/S on August 30, 2026. The term sheet sets forth terms for a global settlement and license agreement that, the company disclosed, "resolves all pending proceedings relating to the BioMarin Patent Rights." The license covers research, development, manufacture, use, sale, and commercialization of Licensed Products for all current and potential indications, including achondroplasia and hypochondroplasia, and in combination with other medicines.

The filing specifies that Ascendis will pay royalties equal to 20% of annual net sales of Licensed Products in the United States and 18% of annual net sales in the European Union, Brazil, and South Korea. These rates apply from the date of first commercial sale in each respective territory, "applied retroactively, as applicable," and run until May 2030. In connection with the settlement, the filing states the parties will dismiss with prejudice all pending litigation relating to the BioMarin Patent Rights.

The term sheet also includes a mutual regulatory non-interference clause and a release by BioMarin of infringement claims against Ascendis arising before the August 30, 2026 effective date. The filing notes the parties agreed to negotiate a full agreement in good faith, with a target date of September 24, 2026. If that agreement is not executed by that date, the term sheet provisions "will continue to be binding on the parties." The filing also notes that forward-looking statements in the report are subject to risks and uncertainties, including BioMarin's ability to enforce the term sheet or agreement and actual sales of Licensed Products, as further described in BioMarin's filings with the SEC.

What Was Disclosed

BioMarin disclosed the execution of a binding term sheet with Ascendis Pharma A/S establishing royalty rates, a worldwide non-exclusive license for CNP-based Licensed Products, dismissal of all related litigation, and a deadline of September 24, 2026 for a formal settlement and license agreement.